958 results about "Trimethylsilyl" patented technology

The present invention provides novel thioester derivatives of thiazolyl acetic acid of the general formula (I),wherein, R1 represents H, trityl, CH3, or CRaRbCOOR3, in which Ra and Rb, independently of one another, represents hydrogen or methyl and R3 represents H or C1-C7 alkyl; and R2 represents C1-C4 alkyl or phenyl. The invention also provides a method for preparation of the thioester derivatives and reaction of the thioester derivatives with cephem carboxylic acids to produce cephalosporin antibiotic compounds having general formula (II),wherein, R1 represents H, trityl, CH3, or CRaRbCOOR3, in which Ra and Rb, independently of one another, represents hydrogen or methyl and R3 represents H or C1-C7 alkyl; R4 is CH3, -CH=CH2, CH2OCH3, CH2OCOCH3,and R5 is H or a salt or a carboxylic protecting group, comprising,acylating a compound of formula (III),wherein, R4 and R5 are defined as above, and R6 is H or trimethylsilyl;with a compound of formula (I).

A hybrid contact lens includes a substantially rigid center portion and a substantially flexible skirt portion connected to the center portion. The skirt portion is formed using xerogels compatible with diluents comprising at least one selected from polylactic acid, polyglycolic acid, lactide, glycolide, a polyacetal, a cyclic acetal, a polyketal, a cyclic ketal, a polyorthoester, a cyclic orthoester, di-t-butyl-dicarbonate, tris(trimethylsilyl)amine, and 2,2,2-trifluoroacetamide. These diluents are formulated to function as a stand-in for water in the xerogel polymer, allowing the xerogel to form and bond to the rigid center portion in its fully expanded state. Upon hydration of the hybrid lens, substantially little dimensional change, and thus substantially little distortion, is obtained in the skirt portion. The diluents of the present invention further preserve the mechanical integrity of the xerogel, allowing the xerogel to be machined to final shape, improving the dimensional tolerances which can be achieved in the hybrid lens.

The present invention is one kind of 17-hydroxy C27 steroid compound and its synthesis and use. The synthesis process of the present invention is simple and suitable for industrial production in synthesizing pennogenin as well as dihydro pennogenin and OSW-1 aglycone analog.

A rechargeable lithium cell comprising a cathode, an anode, a non-flammable quasi-solid electrolyte containing a lithium salt dissolved in a mixture of a liquid solvent and a liquid additive having a salt concentration from 1.5 M to 5.0 M so that said electrolyte exhibits a vapor pressure less than 0.01 kPa, a vapor pressure less than 60% of the vapor pressure of the liquid solvent alone, a flash point at least 20 degrees Celsius higher than the flash point of the liquid solvent alone, a flash point higher than 150° C., or no flash point, wherein the liquid additive is selected from Hydrofluoro ether (HFE), Trifluoro propylene carbonate (FPC), Methyl nonafluorobutyl ether (MFE), Fluoroethylene carbonate (FEC), Tris(trimethylsilyl)phosphite (TTSPi), Triallyl phosphate (TAP), Ethylene sulfate (DTD), 1,3-propane sultone (PS), Propene sultone (PES), Diethyl carbonate (DEC), Alkylsiloxane (Si—O), Alkylsilane (Si—C), liquid oligomeric silaxane (—Si—O—Si—), Tetraethylene glycol dimethylether (TEGDME), or a combination thereof.

Methods of fabricating a lanthanum oxide layer, and methods of fabricating a MOSFET and/or a capacitor especially adapted for semiconductor applications using such a lanthanum oxide layer are disclosed. The methods include a preliminary step of disposing a semiconductor substrate into a chamber. Tris(bis(trimethylsilyl)amino)Lanthanum as a lanthanum precursor is then injected into the chamber such that the lanthanum precursor is chemisorbed on the semiconductor substrate. Then, after carrying out a first purge of the chamber, at least one oxidizer is injected into the chamber such that the oxidizer is chemisorbed with the lanthanum precursor on the semiconductor substrate. Then, the chamber is purged a second time. The described steps of injecting the lanthanum precursor into the chamber, first-purging the chamber, injecting an oxidizer into the chamber, and second-purging the chamber may be sequentially and repeatedly performed to form a lanthanum oxide layer of a desired thickness having enhanced semiconductor characteristics.

Disclosed herein are compounds of the formula

wherein R₁ is independently H or alkyl of 1 to 6 carbons;

• R₂ is optional and is defined as lower alkyl of 1 to 6 carbons, F, Cl, Br, I, CF₃, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons;
• n is an integer of between 0 and 2;
• o is an integer between 0 and 3;
• R₃ is hydrogen, lower alkyl of 1 to 6 carbons, F, Cl, Br or I;
• R₄ is heteroaryl or (R₅)_p-heteroaryl where the heteroaryl group is 5-membered or 6-membered and has 1 to 3 heteroatoms selected from the group consisting of O, S, and N;
• p is an integer having the values of 0–5;
• R₅ is F, Cl, Br, I, NO₂, N(R₈)₂, N(R₈)CORO₈, N(R₈)CON(R₈)₂, OH, OCOR₈, OR₈, CN, COOH, COOR₈, C_1-10 alkyl, fluoro substituted C_1-10 alkyl, C_2-10 alkenyl having 1 to 3 double bonds, C_2-10 alkynyl having 1 to 3 triple bonds, or a (trialkyl)silyl or (trialkyl)silyloxy group where the alkyl groups independently have 1 to 6 carbons;
• A is (CH₂)_q where q is 0–5, C_3-6 branched alkyl, C_3-6 cycloalkyl, C_2-6 alkenyl having 1 or 2 double bonds, or C_2-6 alkynyl having 1 or 2 triple bonds;
• B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COORO₈, CONR₉R₁₀, CH₂OH, CH₂OR₁₁, CH₂OCOR₁₁, CHO, CH(OR₁₂)₂, CHOR₁₃O, COR₇, CR₇(OR₁₂)₂, CR₇OR₁₃O, or Si(C_1-6alkyl)3;
• R₇ is C_1-5 alkyl, C_3-5 cycloalkyl, or C_2-5 alkenyl;
• R₈ is C_1-10 alkyl, C_1-10 (trimethylsilyl)alkyl, or C_5-10 cycloalkyl;
• R₉ and R₁₀ are independently hydrogen, C_1-10 alkyl, C_5-10 cycloalkyl, phenyl or R₁₂-phenyl;
• R₁₁ is C_1-6 alkyl, phenyl, or R₁₂-phenyl;
• R₁₂ is C_1-6 alkyl; and
• R₁₃ is divalent alkyl radical of 2–5 carbons.

The present invention relates to leave-on compositions for personal care comprising trimethylsilylalkylsilsesquioxanes, particularly trimethylsilyl-n-octylsilsesquioxanes (Caprylyl Trimethicones). Said trimethylsilylalkylsilsesquioxanes are especially useful in formulating emulsions.

A medical device with a hydrophilic and lubricious coating, wherein the coating includes a hydrophilic polymeric unit layer deposited on the medical device and cross-linked with a plasma deposited double bond monomer. The hydrophilic polymeric unit can include ethylene oxide with one or more primary or secondary alcohol groups or glycosaminoglycans such as hyaluronic acid, and the double bond monomer includes monomers containing at least one double bond, preferably a C═C, C═N or C═O bond, including N-trimethylsilyl-allylamine, ethylene, propylene and allyl alcohol.

The invention relates to the technical field of lithium ion batteries, in particular to an electrolyte suitable for a silicon-carbon negative electrode lithium ion battery and the silicon-carbon negative electrode lithium ion battery. The electrolyte suitable for the lithium ion battery is prepared from a non-aqueous organic solvent, lithium salt and additives. The additives comprise fluoroethylene carbonate, tris(trimethylsilyl) borate and a sulphate compound with the formula (1) or the formula (2). Compared with the prior art, under the synergistic effect of the three additives in combined use, the capability of changing and controlling SEI composition and stability is achieved, the overall impedance of a formed SEI film is small, and the components and the structure of the SEI film are stable, so that the reversible capacity of the silicon-carbon negative electrode lithium ion battery is greatly increased, the actual discharge capability of the silicon-carbon negative electrode lithium ion battery is greatly improved, then the battery has good cycle performance and good high-and-low temperature performance, and it is guaranteed that the battery can be used within a wide ambient temperature range.

A compound having GSK-3 inhibiting function.

A¹ and A³ are a single bond, an aliphatic hydrocarbon group; A² and A⁴ are a single bond, CO, COO, CONR, O, OCO, NR, NRCO, NRCOO, etc.; G¹ is a single bond, an aliphatic hydrocarbon, aromatic hydrocarbon, heterocyclic; G² is a hydrogen atom, an aliphatic hydrocarbon, an alicyclic hydrocarbon, an aromatic hydrocarbon, heterocyclic; A⁵ is a single bond, NR; R² is H, halogen, an aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; A⁶ is a single bond, NR, CO, NRCO, NRCONR, CONR, COO, O, etc.; R³ is H, halogen, nitro, saturated aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; and when A⁶ is CR═CR or C≡C; R³ may be a trimethylsilyl, formyl, acyl, carboxyl, alkoxylcarbonyl, carbamoyl, alkylcarbamoyl or cyano group; and R is H or an aliphatic hydrocarbon group.

The invention provides a method for preparing chiral 4-substituted dihydrofuran-2(3H)-ketone. The method comprises the following steps: (a) dropwise adding acyl chloride (3) into an organic solvent solution of a compound (1), enabling reaction to obtain an acyl chloride intermediate solution, then dropwise adding an organic solvent solution of a compound (2) and enabling reaction to obtain a compound (4); (b) dropwise adding a bis(trimethylsilyl)amide alkali metal salt solution into an organic solvent solution of the compound (4), enabling reaction, dropwise adding a compound (5) into the obtained reaction liquid and enabling reaction to obtain a compound (6); (c) enabling reaction between the compound (6) and alkali to obtain a compound (7); (d) enabling reaction between the compound (7) and a reducing agent to obtain a compound (8), wherein R is selected from aryl, arylmethyl or alkyl, R1, R2 and R3 are independently selected from alkyl, and X is selected from Cl, Br or I. The method is simple in process, strong in operability and easy for industrial production. The reaction route is shown in the description.

Disclosed is a liquid chemical for forming a water-repellent protecting film at least on a surface of a recessed portion of an uneven pattern at the time of cleaning a wafer having a finely uneven pattern at its surface and containing silicon at least a part of the uneven pattern. This liquid chemical contains a silicon compound A represented by the general formula: R¹_aSi(H)_bX_4-a-b and an acid A, the acid A being at least one selected from the group consisting of trimethylsilyl trifluoroactate, trimethylsilyl trifluoromethanesulfonate, dimethylsilyl trifluoroactate, dimethylsilyl trifluoromethanesulfonate, butyldimethylsilyl trifluoroactate, butyldimethylsilyl trifluoromethanesulfonate, hexyldimethylsilyl trifluoroacetate, hexyldimethylsilyl trifluoromethanesulfonate, octyldimethylsilyl trifluoroactate, octyldimethylsilyl trifluoromethanesulfonate, decyldimethylsilyl trifluoroacetate and decyldimethylsilyl trifluoromethanesulfonate.

The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

A first compound having an atom in an oxidized state is reacted with a bis(trimethylsilyl) six-membered ring system or related compound to form a second compound having the atom in a reduced state relative to the first compound. The atom in an oxidized state is selected from the group consisting of Groups 2-12 of the Periodic Table, the lanthanides, As, Sb, Bi, Te, Si, Ge, Sn, and Al.